New drug targets fatty liver in genetically At-Risk patients

NCT ID NCT05395481

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug, LY3849891, in 115 people with fatty liver disease who carry a specific gene variant (PNPLA3 I148M). The main goal was to check safety and how the body processes the drug. Researchers also looked at changes in liver fat and inflammation using MRI and blood tests. The study lasted up to 32 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3849891
What this could lead to: If successful, this could point toward a treatment for fatty liver disease in people with a specific genetic risk factor.
What could go wrong: This is an early Phase 1 trial focused on safety, not proof of effectiveness. The drug may not work or could have side effects. It only applies to people with the PNPLA3 I148M gene variant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver fatty liver disease metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

Contacts and locations

Locations

Accel Research Sites - Maitland

Maitland, Florida, 32751, United States
Advanced Pharma Clinical Research

Miami, Florida, 33175, United States
Arizona Liver Health - Chandler

Chandler, Arizona, 85225, United States
Charter Research - Winter Park

Orlando, Florida, 32803, United States
Clinical Research Hospital Tokyo

Shinjuku-ku, 160-0004, Japan
Clinical Trials of Texas, Inc.

San Antonio, Texas, 78229, United States
Evolution Clinical Trials, Inc

Miami, Florida, 33122, United States
FDI Clinical Research

San Juan, 00927, Puerto Rico
Floridian Clinical Research

Miami Lakes, Florida, 33016, United States
Houston Research Institute

Houston, Texas, 77079, United States
IU Health University Hospital

Indianapolis, Indiana, 46290, United States
Inland Empire Clinical Trials, LLC

Rialto, California, 92377, United States
Orange County Research Center

Orange, California, 92868, United States
P-One Clinic

Hachiōji, 192-0071, Japan
Pinnacle Clinical Research

San Antonio, Texas, 78229, United States
Synergy Healthcare LLC

Brandon, Florida, 33511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.